menu search

Nextech ar solutions launches public version of aritize 3d saas for ecommerce

Nextech AR Solutions Corp. (CSE:NTAR, OTCQB:NEXCF, neo:NTAR) announced it has launched its ARitize 3D S...

January 20, 2022, 8:58 am

Nextech ar solutions launches public version of aritize 3d saas for ecommerce

Nextech AR Solutions Corp. (CSE:NTAR, OTCQB:NEXCF, neo:NTAR) announced it has launched its ARitize 3D S...

January 20, 2022, 8:58 am

Cardiovascular systems, orbusneich scores fda approval for scoreflex scoring balloon

Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex N...

January 20, 2022, 8:51 am

Cardiovascular systems, orbusneich scores fda approval for scoreflex scoring balloon

Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex N...

January 20, 2022, 8:51 am

Cardiovascular systems, orbusneich scores fda approval for scoreflex scoring balloon

Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex N...

January 20, 2022, 8:51 am

Royalty pharma to announce fourth-quarter and full-year 2021 financial results on february 15, 2022

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 202...

January 20, 2022, 7:45 am

Royalty pharma to announce fourth-quarter and full-year 2021 financial results on february 15, 2022

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 202...

January 20, 2022, 7:45 am

Royalty pharma to announce fourth-quarter and full-year 2021 financial results on february 15, 2022

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 202...

January 20, 2022, 7:45 am

U.s. xpress enterprises, inc. announces fourth quarter and full year 2021 earnings release date

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--U.S. Xpress Enterprises, Inc. (NYSE: USX) today announced that it will release its fourth quarter and full year 2...

January 19, 2022, 4:15 pm

U.s. xpress enterprises, inc. announces fourth quarter and full year 2021 earnings release date

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--U.S. Xpress Enterprises, Inc. (NYSE: USX) today announced that it will release its fourth quarter and full year 2...

January 19, 2022, 4:15 pm

U.s. xpress enterprises, inc. announces fourth quarter and full year 2021 earnings release date

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--U.S. Xpress Enterprises, Inc. (NYSE: USX) today announced that it will release its fourth quarter and full year 2...

January 19, 2022, 4:15 pm

Polarityte (pte) gets fda nod to begin pivotal ulcer study

PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cuta...

January 19, 2022, 1:05 pm

Polarityte (pte) gets fda nod to begin pivotal ulcer study

PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cuta...

January 19, 2022, 1:05 pm

Polarityte (pte) gets fda nod to begin pivotal ulcer study

PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cuta...

January 19, 2022, 1:05 pm

Why chemocentryx shares are rising

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVneo...

January 19, 2022, 11:29 am

Why chemocentryx shares are rising

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVneo...

January 19, 2022, 11:29 am

Why chemocentryx shares are rising

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVneo...

January 19, 2022, 11:29 am

Cvrx: the path to 7x investment returns

BaroStim neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market...

January 7, 2022, 1:18 pm

Cvrx: the path to 7x investment returns

BaroStim neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market...

January 7, 2022, 1:18 pm

Cvrx: the path to 7x investment returns

BaroStim neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market...

January 7, 2022, 1:18 pm


Search within

Pages Search Results: